Efficacy of Memantine [N- Methyl- D- Aspartate (NMDA) receptor antagonist] versus placebo in acute non arteritic anterior ischemic optic neuropathy (NAION)
Phase 2
Active, not recruiting
- Conditions
- on arteritic anterior ischemic optic neuropathy (NAION)Non arteritic anterior ischemic optic neuropathy (NAION)Neurological - Diseases / disorders of the eye
- Registration Number
- ACTRN12607000181404
- Lead Sponsor
- Tehran University of Medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Unilateral acute onset of painless visual loss, localized or generalized edema and paleness of the optic nerve head, flame shaped hemorrhages, arterial narrowing without venous congestion and RAPD (relative afferent pupillary defect) in acute phase (=8 weeks) along with visual field defect consistent with non arteritic AION in perimetry.
Exclusion Criteria
Pregnancy and breast feeding, complete optic disc atrophy that other etiologies were suggested, presence of systemic signs and symptoms such as fever, headache… consistent with arteritic AION, drug history such as anti-convulsants, barbiturates, neuroleptics, Amantadine hydrochlorothiazids and history of renal insufficiency.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Any change in visual acuity[Baseline, then on week 3, months 3 and 6]
- Secondary Outcome Measures
Name Time Method Any change of VEP (visual evoked potential) parameters (amplitude and latency) and automated perimetry parameters.[From baseline with month 3.]